The role of litigation in defining drug risks

被引：46

作者：

Kesselheim, Aaron S. ^{[1
]}

Avorn, Jerry ^{[1
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2007年 / 297卷 / 03期

关键词：

D O I：

10.1001/jama.297.3.308

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：308 / 311

页数：4

共 18 条

[1] [Anonymous], 2005, NY TIMES 0225
[2] Avorn J., 2005, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, VRevised, Updated edition, DOI DOI 10.1200/JOP.2014.003194
[3] BACIU A, 2006, FUTURE DRUG SAFETY P
[4] BERENSON A, 2003, NY TIMES 0921, pA1
[5] Berenson Alex, 2006, N Y Times Web, pC2
[6] BENDECTIN - REVIEW OF THE MEDICAL LITERATURE OF A COMPREHENSIVELY STUDIED HUMAN NONTERATOGEN AND THE MOST PREVALENT TORTOGEN-LITIGEN
BRENT, RL
[J]. REPRODUCTIVE TOXICOLOGY, 1995, 9 (04) : 337 - 349
[7] Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8
Curfman, GD
Morrissey, S
Drazen, JM
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (26) : 2813 - 2814
[8] The influence of money on medical science
DeAngelis, Catherine D.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (08): : 996 - 998
[9] Food and Drug Administration HHS, 2006, Fed Regist, V71, P3921
[10] FR (Federal Register), 1985, FED REGISTER, V50, P7452